Category Archives: Press Releases

SOM Biotech Announces Initiation of Phase 2a Clinical Trial of SOM3355 in Huntington’s Disease Patients

BARCELONA, Spain and CAMBRIDGE, Massachusetts, July 17, 2018 — SOM Biotech, a clinical-stage biopharmaceutical company that discovers and develops drugs for orphan indications in the Central Nervous System, has announced today the successful initiation of Phase 2a clinical trial of its repurposed compound SOM3355 for the treatment of the chorea movements associated to Huntington’s disease. The Principal Investigator of the study is …

Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®)

SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension therapy bevantolol (Calvan®). SOM, after using a proprietary ligand analysis computational algorithm and completing the preclinical assays, determined that bevantolol (coded SOM3355 by SOM) is a highly effective Vesicular Monoamine Transporter Type 2 (VMAT2) inhibitor, a class of compounds that …

SOM Biotech licenses its first product and expands to the United States

The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system diseases, has concluded a worldwide license agreement with Corino Therapeutics Inc. to clinically develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement had been reached, the drug achieved very promising results in a Phase 2 …

SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis.

SOM Biotech Ltd (SOM) a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases, today announces an exclusive worldwide license agreement with U.S. based Corino Therapeutics, Inc. (Corino), for the clinical development and commercialization of SOM0226 (CRX-1008), a drug for the treatment of Transthyretin Amyloidosis (ATTR). …